270 related articles for article (PubMed ID: 29772652)
1. Gp120 V5 Is Targeted by the First Wave of Sequential Neutralizing Antibodies in SHIV
Jia M; Lu H; Kong XP; Cheng-Mayer C; Wu X
Viruses; 2018 May; 10(5):. PubMed ID: 29772652
[TBL] [Abstract][Full Text] [Related]
2. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
[TBL] [Abstract][Full Text] [Related]
3. Development of broad neutralization activity in simian/human immunodeficiency virus-infected rhesus macaques after long-term infection.
Gao N; Wang W; Wang C; Gu T; Guo R; Yu B; Kong W; Qin C; Giorgi EE; Chen Z; Townsley S; Hu SL; Yu X; Gao F
AIDS; 2018 Mar; 32(5):555-563. PubMed ID: 29239895
[TBL] [Abstract][Full Text] [Related]
4. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
[TBL] [Abstract][Full Text] [Related]
5. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
[TBL] [Abstract][Full Text] [Related]
6. Development of Antibodies with Broad Neutralization Specificities against HIV-1 after Long Term SHIV Infection in Macaques.
Gao N; Gai Y; Meng L; Wang C; Zhang X; Wang W; Qin C; Yu X; Gao F
Viruses; 2020 Jan; 12(2):. PubMed ID: 32023860
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
[TBL] [Abstract][Full Text] [Related]
8. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
9. The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection.
Charles TP; Burton SL; Arunachalam PS; Cottrell CA; Sewall LM; Bollimpelli VS; Gangadhara S; Dey AK; Ward AB; Shaw GM; Hunter E; Amara RR; Pulendran B; van Gils MJ; Derdeyn CA
PLoS Pathog; 2021 Feb; 17(2):e1009257. PubMed ID: 33556148
[TBL] [Abstract][Full Text] [Related]
10. Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge.
Julg B; Tartaglia LJ; Keele BF; Wagh K; Pegu A; Sok D; Abbink P; Schmidt SD; Wang K; Chen X; Joyce MG; Georgiev IS; Choe M; Kwong PD; Doria-Rose NA; Le K; Louder MK; Bailer RT; Moore PL; Korber B; Seaman MS; Abdool Karim SS; Morris L; Koup RA; Mascola JR; Burton DR; Barouch DH
Sci Transl Med; 2017 Sep; 9(406):. PubMed ID: 28878010
[TBL] [Abstract][Full Text] [Related]
11. Mucosal transmissibility, disease induction and coreceptor switching of R5 SHIVSF162P3N molecular clones in rhesus macaques.
Ren W; Mumbauer A; Zhuang K; Harbison C; Knight H; Westmoreland S; Gettie A; Blanchard J; Cheng-Mayer C
Retrovirology; 2013 Jan; 10():9. PubMed ID: 23369442
[TBL] [Abstract][Full Text] [Related]
12. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
[TBL] [Abstract][Full Text] [Related]
13. Induction of neutralizing antibodies against tier 2 human immunodeficiency virus 1 in rhesus macaques infected with tier 1B simian/human immunodeficiency virus.
Himeno A; Ishida Y; Mori H; Matsuura K; Kikukawa M; Sakawaki H; Miura T
Arch Virol; 2019 May; 164(5):1297-1308. PubMed ID: 30820667
[TBL] [Abstract][Full Text] [Related]
14. Breadth and magnitude of antigen-specific antibody responses in the control of plasma viremia in simian immunodeficiency virus infected macaques.
Pahar B; Kenway-Lynch CS; Marx P; Srivastav SK; LaBranche C; Montefiori DC; Das A
Virol J; 2016 Dec; 13(1):200. PubMed ID: 27903274
[TBL] [Abstract][Full Text] [Related]
15. Consistent patterns of change during the divergence of human immunodeficiency virus type 1 envelope from that of the inoculated virus in simian/human immunodeficiency virus-infected macaques.
Blay WM; Gnanakaran S; Foley B; Doria-Rose NA; Korber BT; Haigwood NL
J Virol; 2006 Jan; 80(2):999-1014. PubMed ID: 16379001
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.
Ditse Z; Muenchhoff M; Adland E; Jooste P; Goulder P; Moore PL; Morris L
J Virol; 2018 Sep; 92(17):. PubMed ID: 29950423
[TBL] [Abstract][Full Text] [Related]
17. Characterization of primary isolate-like variants of simian-human immunodeficiency virus.
Crawford JM; Earl PL; Moss B; Reimann KA; Wyand MS; Manson KH; Bilska M; Zhou JT; Pauza CD; Parren PW; Burton DR; Sodroski JG; Letvin NL; Montefiori DC
J Virol; 1999 Dec; 73(12):10199-207. PubMed ID: 10559336
[TBL] [Abstract][Full Text] [Related]
18. Diversification in the HIV-1 Envelope Hyper-variable Domains V2, V4, and V5 and Higher Probability of Transmitted/Founder Envelope Glycosylation Favor the Development of Heterologous Neutralization Breadth.
Smith SA; Burton SL; Kilembe W; Lakhi S; Karita E; Price M; Allen S; Hunter E; Derdeyn CA
PLoS Pathog; 2016 Nov; 12(11):e1005989. PubMed ID: 27851829
[TBL] [Abstract][Full Text] [Related]
19. Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque.
Walker LM; Sok D; Nishimura Y; Donau O; Sadjadpour R; Gautam R; Shingai M; Pejchal R; Ramos A; Simek MD; Geng Y; Wilson IA; Poignard P; Martin MA; Burton DR
Proc Natl Acad Sci U S A; 2011 Dec; 108(50):20125-9. PubMed ID: 22123961
[TBL] [Abstract][Full Text] [Related]
20. Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.
Kilgore KM; Murphy MK; Burton SL; Wetzel KS; Smith SA; Xiao P; Reddy S; Francella N; Sodora DL; Silvestri G; Cole KS; Villinger F; Robinson JE; Pulendran B; Hunter E; Collman RG; Amara RR; Derdeyn CA
J Virol; 2015 Aug; 89(16):8130-51. PubMed ID: 26018167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
